

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Allan J. TOBIN et al.

Application No.: 10/641,149

Filed: August 15, 2003

For: CLONED GLUTAMIC ACID
DECARBOXYLASE



Group Art Unit: 1656

Examiner: Gabriele E. Bugaisky

Confirmation No.: 9827

SECOND INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. § 1.56, the references listed on the attached Form PTO-1449 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application.

I. Timing of the Information Disclosure Statement:

This Information Disclosure Statement is filed:

- ☐ With the new patent application submitted herewith (37 C.F.R. § 1.97(a)).
- ☐ Within three months after the filing date of the application or within three months after the date of entry of the national stage of a PCT application as set forth in 37 C.F.R. § 1.491.
- ☐ Before the mailing date of a first Office action on the merits. In the event, however, that an Office Action has crossed in the mail with this Information Disclosure Statement, the Commissioner is hereby authorized to charge Deposit Account No. 50-2518 for any fees required pursuant to 37 C.F.R. §§ 1.17(p) or 1.17(i)(1).
- ☒ After a first Office Action on the merits but prior to the closing of prosecution, therefore under 37 C.F.R. § 1.97(c), the fee set forth in 37 C.F.R. § 1.17(p) is enclosed. This fee (\$180) should be charged to the undersigned's Deposit Account No. 50-2518.

II. Copies of the Cited Items:

- ☒ Copies of all of the items listed on the attached Form PTO-1449 are enclosed.
- ☐ Copies of only the following items listed on the attached Form PTO-1449 are enclosed: _____.

- ☐ Copies of items listed on the attached Form PTO-1449 are not supplied because they were previously cited by or submitted to the Patent Office in prior Application No. _____, filed _____, and relied upon in this application for an earlier filing date under 35 U.S.C § 120.
See 37 C.F.R. § 1.98(d).
- ☐ Copies of those items which are marked with an asterisk (**) in the attached Form PTO-1449 were cited in a foreign examination report in a related case. A copy of the search report and the cited references not already of record in this application are attached hereto.
- ☐ Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed. However, copies of the listed U.S. Patents and U.S. Patent Application Publications are not enclosed since it is no longer required.

III. Conclusion:

Citation of the above documents shall not be construed as:

1. an admission that the documents are necessarily prior art with respect to the instant invention;
2. a representation that a search has been made, other than as described above; or
3. an admission that the information cited herein is, or is considered to be, material to patentability as defined in § 1.56(b).

It is respectfully requested that the Examiner indicate consideration of the cited references by returning a copy of the attached form PTO 1449 with initials or other appropriate marks.

The Commissioner is hereby authorized to charge Deposit Account No. 50-2518 for any additional fees required in connection with the filing of this Information Disclosure Statement.

Respectfully submitted,
BINGHAM MCCUTCHEN, L.L.P.

Date: July 24, 2006


By: 

Erin M. Dunston
Registration No. 51,147

Bingham McCutchen LLP
Three Embarcadero Center
San Francisco, California 94111-4067
Local Telephone: (202) 373-6000
Local Facsimile: (202) 373-6001

SECOND INFORMATION DISCLOSURE STATEMENT BY APPLICANT

JUL 24 2006

**Complete if Known**

Application Number	10/641,149
Filing Date	August 15, 2003
First Named Inventor	Allan J. TOBIN et al.
Examiner Name	Gabriele E. Bugaisky
Confirmation No.	9827
Group Art Unit	1656
Attorney Docket Number	704611-3001

Sheet

1

of

U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	STATUS						
					Translation	Partial Translation	Eng. Lang. Summary	Search Report	IPER	Abstract	Cited in Spec

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	T.A. M.A. Al-Bukhari et al., "Distinct antigenic features of linear epitopes at the N-terminus and C-terminus of 65 kDa glutamic acid decarboxylase (GAD65): implications for autoantigen modification during pathogenesis," 130 CLIN. EXP. IMMUNOL. 131-139 (2002).
	J-M. Bach et al., "High Affinity Presentation of an Autoantigenic Peptide in Type I Diabetes by an HLA Class II Protein Encoded in a Haplotype Protecting From Disease," 10 JOURNAL OF AUTOIMMUNITY 375-386 (1997).
	A. Falorni et al., in "Diagnostic sensitivity of immunodominant epitopes of glutamic acid decarboxylase (GAD65) autoantibodies in childhood IDDM," 39 DIABETOLOGIA 1091-1098 (1996).
	E. Harfouch-Hammoud et al., in "Identification of Peptides From Autoantigens GAD65 and IA-2 That Bind to HLA Class II Molecules Predisposing to or Protecting From Type 1 Diabetes," 48 DIABETES 1937-1947 (Oct. 1999).
	D. Kaufman et al., "Autoimmunity to Two Forms of Glutamate Decarboxylase in Insulin-dependent Diabetes Mellitus," 89 J. CLIN. INVEST. 283-292 (Jan. 1992).
	T. Kobayashi et al., in "Unique Epitopes of Glutamic Acid Decarboxylase Autoantibodies in Slowly Progressive Type 1 Diabetes," 88(10) THE JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM 4768-4775 (2003).
	L. Li et al., "Differential Detection of Rat Islet and Brain Glutamic Acid Decarboxylase (GAD) Isoforms with Sequence-specific Peptide Antibodies," 43(1) THE JOURNAL OF HISTOCHEMISTRY AND CYTOCHEMISTRY 53-59 (1995).
	T. Lohmann et al., "Humoral and Cellular Autoimmune Responses in Stiff person Syndrome," 998 ANN. N.Y. ACAD. SCI. 998 215-222 (2003).
	T. Lohmann et al., "Immunodominant epitopes of glutamic acid decarboxylase 65 and 67 in insulin-dependent diabetes mellitus," 343 THE LANCET 1607-1608 (June 25, 1994).
	T. Lohmann et al., "T cell Clones to Epitopes of Glutamic Acid Decarboxylase 65 Raised from Normal Subjects and Patients with Insulin-dependent Diabetes," 9 JOURNAL OF AUTOIMMUNITY 385-389 (1996).
	M. A. Myers et al., "A Diabetes-Related Epitope of GAD65: A Major Diabetes-Related Conformational Epitope on GAD65," 1005 ANNALS OF THE NEW YORK ACADEMY OF SCIENCES 250-252 (2003).
	P. Panina-Bordignon et al., "Cytotoxic T Cells Specific For Glutamic Acid Decarboxylase in Autoimmune Diabetes," J. EXP. MED. 1923-1927 (May 1995).
	Salil D. Patel et al., in "Identification of immunodominant T cell epitopes of human glutamic acid decarboxylase 65 by using HLA-DR ($\alpha 1^*0101, \beta 1^*0401$) transgenic mice," 94 PROC. NATL. ACAD. SCI. USA 8082-87 (July 1997).
	A. C. Powers et al., "Comparative analysis of epitope recognition of glutamic acid decarboxylase (GAD) by autoantibodies from different autoimmune disorders," 118 CLINICAL AND EXPERIMENTAL IMMUNOLOGY 349-356 (1999).

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

SECOND INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	10/641,149
				Filing Date	August 15, 2003
				First Named Inventor	Allan J. TOBIN et al.
				Examiner Name	Gabriele E. Bugaisky
				Confirmation No.	9827
				Group Art Unit	1656
Sheet	2	of	2	Attorney Docket Number	704611-3001

NON-PATENT LITERATURE DOCUMENTS	
Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	Anthony Quinn & Eli E. Sercarz, "T Cells with Multiple Fine Specificities are Used by Non-obese Diabetic (NOD) Mice in the Response to GAD(524-543)," 9 JOURNAL OF AUTOIMMUNITY 365-370 (1996).
	F. Rharbaoui et al., in "Peptide specificity of high-titer anti-glutamic acid decarboxylase (GAD)65 autoantibodies," 62 IMMUNOLOGY LETTERS 123-130 (1998).
	Y. Shi et al., "Amino Acid Residues 24-31 but not Palmitoylation of Cysteines 30 and 45 Are Required for Membrane Anchoring of Glutamic Acid Decarboxylase, GAD ₆₅ ," 124(6) THE JOURNAL OF CELL BIOLOGY 927-934 (March 1994).
	M. Solimena et al., "A Signal Located within Amino Acids 1-27 of GAD65 Is Required for Its Targeting to the Golgi Complex Region," 126(2) THE JOURNAL OF CELL BIOLOGY 331-341 (July 1994).
	K. Syren et al., "Immune Reactivity of Diabetes-Associated Human Monoclonal Autoantibodies Defines Multiple Epitopes and Detects Two Domain Boundaries in Glutamate Decarboxylase," THE JOURNAL OF IMMUNOLOGY 5208-5214 (1996).
	M. A. Zechel et al., in "Characterization of Novel T-cell Epitopes on 65 kDa and 67 kDa Glutamic Acid Decarboxylase Relevant in Autoimmune Responses in NOD Mice," 11 JOURNAL OF AUTOIMMUNITY 83-95 (1998).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.